- Home
- NERV vs NEPH Comparison
NERV vs NEPH Comparison
Compare NERV & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- NEPH
- Stock Information
- Founded
- NERV 2007
- NEPH 1997
- Country
- NERV United States
- NEPH United States
- Employees
- NERV N/A
- NEPH N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- NEPH Medical/Dental Instruments
- Sector
- NERV Health Care
- NEPH Health Care
- Exchange
- NERV Nasdaq
- NEPH Nasdaq
- Market Cap
- NERV 15.5M
- NEPH 16.8M
- IPO Year
- NERV 2014
- NEPH 2004
- Fundamental
- Price
- NERV $1.82
- NEPH $1.53
- Analyst Decision
- NERV Hold
- NEPH Buy
- Analyst Count
- NERV 1
- NEPH 1
- Target Price
- NERV $5.00
- NEPH $5.00
- AVG Volume (30 Days)
- NERV 77.1K
- NEPH 19.2K
- Earning Date
- NERV 03-04-2025
- NEPH 03-06-2025
- Dividend Yield
- NERV N/A
- NEPH N/A
- EPS Growth
- NERV N/A
- NEPH N/A
- EPS
- NERV N/A
- NEPH N/A
- Revenue
- NERV N/A
- NEPH $13,546,000.00
- Revenue This Year
- NERV N/A
- NEPH N/A
- Revenue Next Year
- NERV N/A
- NEPH $9.13
- P/E Ratio
- NERV N/A
- NEPH N/A
- Revenue Growth
- NERV N/A
- NEPH 0.03
- 52 Week Low
- NERV $1.77
- NEPH $1.36
- 52 Week High
- NERV $7.53
- NEPH $3.73
- Technical
- Relative Strength Index (RSI)
- NERV 34.70
- NEPH 46.60
- Support Level
- NERV $1.77
- NEPH $1.50
- Resistance Level
- NERV $2.05
- NEPH $1.60
- Average True Range (ATR)
- NERV 0.16
- NEPH 0.10
- MACD
- NERV -0.04
- NEPH -0.01
- Stochastic Oscillator
- NERV 6.41
- NEPH 22.24
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.